ESR1 and breast carcinoma: This present study concludes that as a rule of thumb, TAM administration in the adjuvant setting, results in a 30% loss of Estrogen‐receptor expression in ER‐positive patients following tumor progression and this information is pertinent for a clinician to judge the further use of endocrine therapy in metastatic and recurrent breast cancers, where biopsy is not readily available.